VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 28
- Registration Number
- NCT06214052
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: VH4004280 Formulation ADrug: VH4004280 Formulation BDrug: VH4004280 Formulation EDrug: VH4004280 Formulation C
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 46
- Registration Number
- NCT06168318
- Locations
- 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom
Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 3500
- Registration Number
- NCT06134362
- Locations
- 🇺🇬
GSK Investigational Site, Kampala, Uganda
A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 21
- Registration Number
- NCT06061081
- Locations
- 🇪🇸
GSK Investigational Site, Vitoria, Spain
Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults
Phase 2
Active, not recruiting
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 43
- Registration Number
- NCT06039579
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants
Phase 1
Active, not recruiting
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 48
- Registration Number
- NCT06033547
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 208
- Registration Number
- NCT06012136
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
Phase 2
Active, not recruiting
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 135
- Registration Number
- NCT05996471
- Locations
- 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
Phase 3
Recruiting
- Conditions
- HIVHIV Infections
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 412
- Registration Number
- NCT05979311
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
Phase 3
Active, not recruiting
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 171
- Registration Number
- NCT05917509
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
© Copyright 2025. All Rights Reserved by MedPath